Sold as Citanest, Citanest Plain, Citanest Plain Dental. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 22, 2026, FDA lists 3 applications for Prilocaine hydrochloride (sold as Citanest, Citanest Plain, Citanest Plain Dental), first approved Nov 18, 1965, with 0 new uses approved and 0 published complete response letters.
| Nov 18, 1965 | Citanest, Citanest PlainNDA 14763 · New molecular entity | AstraZeneca Pharmaceuticals | 19 | Discontinued |
| Nov 18, 1965 | Citanest Plain DentalNDA 21382 | Dentsply Pharmaceutical | 1 | Discontinued |
| Sep 29, 2010 | Prilocaine HydrochlorideANDA 79235 | Septodont | 1 | Marketed |
| Needlefree Lidocaine Application for Vulvar BiopsiesVulvar Cancers, Vulva Neoplasm · Tufts Medical Center | Not applicable | Not yet recruiting | Aug 28, 2026 |
| Spinal Anesthesia With Bupivacaine Versus Prilocaine on Postoperative Shivering After Inguinal Hernia RepairPostoperative Shivering · Amr mohamed | Phase 4 | Not yet recruiting | May 4, 2026 |
| The Effectiveness of Topical Prilocaine-Lidocaine Cream Plus Acetaminophen and Naproxen Compared to Lidocaine Injection Plus Acetaminophen and Naproxen to Manage Pain During IntraUterine Device InsertionPain During Intrauterine Device Insertion · Monakshi Sawhney | Phase 4 | Not yet recruiting | Apr 22, 2026 |
| Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne ScarsAcne Scars - Atrophic · Assiut University | Not applicable | Not yet recruiting | Mar 13, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA